Malvinder is a dynamic, young business leader who has made a mark on the global landscape by simultaneously pursuing the twin objectives of business for profit and for public good, in a way that positively impacts lives. With the intent of providing broad based world class services through transformative business and delivery models, Malvinder is shaping the contours of the healthcare and financial services industries and driving their evolution. In Healthcare, Malvinder incubated and established Fortis Healthcare Limited, in the late 1990's. Since then, he has been instrumental in transforming it into a leading healthcare delivery company in India and more recently in Asia, as the largest emerging healthcare organisation. With a vision of making quality healthcare services accessible to all, he continues to assiduously pursue this objective, to make it a reality, using innovative business models. In the Financial Services and Insurance sectors, Malvinder has business interests through Religare Enterprises. As Chairman of the company till 2010, he evolved Religare's strategy of creating an integrated financial services organization in India and an emerging global asset management platform. Previously, Malvinder was Chairman, MD and CEO of Ranbaxy Laboratories. He led the expansion of Ranbaxy through a series of strategic partnerships and acquisitions resulting in Ranbaxy becoming a top 10 generic pharmaceutical company, globally. He spearheaded the coming together of Ranbaxy and Daiichi Sankyo, to create the world's fifteenth largest pharmaceutical company – a move seen as a game-changer by industry experts. Malvinder strongly believes in the ability of people to do extraordinary things, in challenging environments. In a precedence setting move, he entrusted the management of Religare to a professional management team by stepping down as Chairman of the company in 2010. He continues to oversee his family's majority interest in Religare, as shareholder. Malvinder has always supported strategic business decisions in the best interest of the companies he has led and continues to lead. The sale of his personal stake in Ranbaxy to Daiichi Sankyo, to secure longevity and a place for Ranbaxy as a top ranking Global Pharmaceutical Company and his decision to exit investments in Parkway Healthcare, emphatically demonstrated his ability to steer his companies, always keeping the best interests of its stakeholders, in mind. Malvinder has a strong personal belief in the social responsibility of individuals and corporates. With a focus on affordability and accessibility to life saving medicines in emerging and under developed countries; he channelled resources towards innovation, to reduce the cost of ARV medication and for the development of a new low cost synthetic anti-malarial drug. He keenly supports initiatives to provide curative and preventive healthcare to the under privileged in India's villages and urban slums through various foundations and trusts. Malvinder is a member of the Board of Visitors at the Fuqua School of Business (Duke University, USA) and the Board of the Indian Council for Research on International Economic Relations (ICRIER). He was a member of the first batch of the Young Global Leaders initiative of the World Economic Forum. A graduate in Economics, he earned his MBA from the Fuqua School of Business, Duke University, USA.

Anti Mlarial